This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ImmunoPrecise Antibodies Past Earnings Performance
Past criteria checks 0/6
Key information
-25.6%
Earnings growth rate
-0.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 28.7% |
| Return on equity | -34.5% |
| Net Margin | -117.4% |
| Last Earnings Update | 31 Jul 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow ImmunoPrecise Antibodies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 22 | 19 | -23 | 19 | 11 |
| 30 Apr 22 | 19 | -17 | 18 | 7 |
| 31 Jan 22 | 19 | -17 | 16 | 6 |
| 31 Oct 21 | 19 | -15 | 16 | 5 |
| 31 Jul 21 | 19 | -10 | 15 | 3 |
| 30 Apr 21 | 18 | -7 | 13 | 2 |
| 31 Jan 21 | 17 | -3 | 12 | 1 |
| 31 Oct 20 | 17 | -3 | 10 | 1 |
| 31 Jul 20 | 15 | -3 | 9 | 1 |
| 30 Apr 20 | 14 | -5 | 9 | 0 |
| 31 Jan 20 | 13 | -8 | 9 | 1 |
| 31 Oct 19 | 11 | -8 | 9 | 1 |
| 31 Jul 19 | 11 | -9 | 9 | 1 |
| 30 Apr 19 | 11 | -8 | 9 | 0 |
| 31 Jan 19 | 10 | -6 | 9 | 1 |
| 31 Oct 18 | 9 | -6 | 9 | 0 |
| 31 Jul 18 | 8 | -5 | 8 | 0 |
| 30 Apr 18 | 5 | -5 | 6 | 1 |
| 31 Jan 18 | 4 | -4 | 5 | 1 |
| 31 Oct 17 | 3 | -7 | 4 | 1 |
| 31 Jul 17 | 2 | -6 | 2 | 1 |
| 30 Apr 17 | 3 | -5 | 2 | 1 |
| 31 Jan 17 | 3 | -4 | 1 | 0 |
| 31 Oct 16 | 3 | 1 | 1 | 0 |
| 31 Jul 16 | 2 | 0 | 1 | 0 |
| 30 Apr 16 | 2 | 0 | 1 | 0 |
Quality Earnings: IPA is currently unprofitable.
Growing Profit Margin: IPA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IPA is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare IPA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (14.4%).
Return on Equity
High ROE: IPA has a negative Return on Equity (-34.51%), as it is currently unprofitable.